You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
|
|---|---|
| Published in |
Annals of the Rheumatic Diseases, May 2008
|
| DOI | 10.1136/ard.2007.085852 |
| Pubmed ID | |
| Authors |
J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, L Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog, N Feltelius |
| Abstract |
Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 3% |
| Germany | 1 | 1% |
| Norway | 1 | 1% |
| United Kingdom | 1 | 1% |
| Brazil | 1 | 1% |
| Denmark | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 71 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 20% |
| Other | 13 | 16% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Doctoral Student | 6 | 8% |
| Student > Bachelor | 6 | 8% |
| Other | 22 | 28% |
| Unknown | 7 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 61% |
| Agricultural and Biological Sciences | 10 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Immunology and Microbiology | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 12 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2016.
All research outputs
#16,681,672
of 26,017,215 outputs
Outputs from Annals of the Rheumatic Diseases
#6,165
of 7,895 outputs
Outputs of similar age
#75,668
of 90,521 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#43
of 47 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,895 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.2. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 90,521 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.